Can a new blood test catch pancreatic cancer early?
Possibly. In a study of 1,785 people from four countries, a blood test called PANXEON caught 86.8% of stage I to II pancreatic cancers. It is still an experimental test, and it is not yet ready to replace other ways of finding this cancer.
Pancreatic cancer has poor outcomes, and finding it earlier is one of the few levers we have. The researchers state the problem plainly: there is no blood test in clinical use that can detect early-stage pancreatic cancer.
This team built one. PANXEON combines two things. The first is a set of 10 microRNAs, which are tiny pieces of genetic material that float in the blood. The second is CA19-9, an existing blood marker for pancreatic cancer. The test blends both into one score. The goal is simple: find the cancer while it is still at an early stage.
What the data show
The study followed people with and without pancreatic cancer across several centers in four countries. It was an observational biomarker study, meaning researchers measured the test against known diagnoses rather than randomly assigning treatment.
The microRNA signature alone did well. In the testing group it caught 83.8% of early-stage cancers. Its overall accuracy score (area under the curve) was 88.6%, where 100% would mean it sorts every person correctly. It also showed little mix-up with other digestive cancers, so it seemed to point at the pancreas specifically.
Adding CA19-9 raised the catch rate to 86.8% for stage I to II cancer. In plain terms, about 87 out of every 100 people with early cancer tested positive. False alarms depended on who was tested. Among low-risk people without cancer, 3.2% got a false positive, about 3 in 100. Among high-risk people without cancer, that rose to 15.6%, about 16 in 100.
Beyond diagnosis: cysts and tracking treatment
Two more findings point to other uses. Some people have high-risk pancreatic cysts, fluid-filled sacs in the pancreas. In these people, the test showed potential for spotting high-grade dysplasia, the stage where cells look abnormal but have not yet become invasive cancer. It reached 64.3% for this.
The second finding came from a small group of 19 people. Their microRNA levels fell during chemotherapy given before surgery, and fell again after surgery. Then the levels rose before the cancer came back. If that holds up in larger groups, a blood test like this could help track whether treatment is working and flag a relapse early.
Dr. Kumar’s Take
This is a promising result in a cancer where we badly need one. A test that catches nearly 9 in 10 early cancers from a blood draw is worth paying attention to.
The false-positive numbers matter just as much. A 3.2% false alarm rate sounds small, but screen a large low-risk population and even a small rate adds up to many people sent for scans and left worrying. The 15.6% false-positive rate in high-risk people is higher still. That is why the authors describe PANXEON as something that may complement existing strategies, not replace them. The recurrence data come from only 19 people, so that part is early. The authors themselves say the test needs larger prospective studies.
Practical Takeaways
- PANXEON is still an investigational test, so it is not something you can order today as a routine screen for pancreatic cancer.
- If you carry a high risk for pancreatic cancer, such as a high-risk pancreatic cyst, ask your doctor about the monitoring options that exist now rather than waiting for a new blood test.
- A positive result on any early-detection blood test is a signal to investigate further, not a diagnosis, because false alarms happen, especially in high-risk groups.
Related Studies and Research
- A simple blood test detects pancreatic cancer early with 92% accuracy
- Blood test trends spot cancer in unexplained weight loss
- A daily pill nearly doubled survival in advanced pancreatic cancer
- Phase I trial of high-dose vitamin C with gemcitabine in pancreatic cancer
- High-dose intravenous vitamin C boosts chemo sensitivity in ovarian cancer
FAQs
What is a liquid biopsy?
A liquid biopsy looks for signs of cancer in a body fluid, usually blood, instead of cutting out a piece of tissue. It measures things that tumors release, such as genetic material. In this study, the test measured 10 microRNAs along with CA19-9. The appeal is that a blood draw is quick and far less invasive than a tissue biopsy or an endoscopy. The trade-off is that a blood signal can point toward cancer, but it cannot confirm it on its own.
Why is CA19-9 alone not enough to find pancreatic cancer early?
CA19-9 is a blood marker linked to pancreatic cancer. The researchers note that no blood test in clinical use today can detect early-stage pancreatic cancer, which is why they built a combined score. In this study, pairing CA19-9 with the microRNA signature pushed early-stage detection from 83.8% with the microRNAs alone to 86.8% with both. Each marker adds information the other misses.
What do the false alarm rates mean for someone at high risk?
In this study, 15.6% of high-risk people without cancer got a false positive, compared with 3.2% of low-risk people without cancer. Put another way, about 16 in every 100 high-risk people who do not have cancer got a worrying result anyway. That is why a positive result needs follow-up testing before anyone draws conclusions, and why the authors frame the test as an add-on to existing strategies.
Bottom Line
A blood test that combines 10 microRNAs with CA19-9 caught 86.8% of stage I to II pancreatic cancers in a 1,785-person international study, with a 3.2% false-positive rate in low-risk people and 15.6% in high-risk people. It also showed promise for spotting high-grade dysplasia in high-risk cysts and for tracking treatment and relapse. It is not ready for routine screening, and it is meant to add to current detection strategies, but it is a real step toward catching this cancer at an early stage.
